Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
AbbVie Q3 2026 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into AbbVie's third quarter 2026 results — and folks, this is another quarter where the raised-guidance train just keeps rolling.
**JORDAN:** It really does. Before we get into it though, let's cover our bases.
**ALEX:** Right — quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Perfect. Now let's get into AbbVie.
**ALEX:** So AbbVie reported adjusted EPS of $3.82, beating guidance by seven cents, and total revenue of $17.4 billion — that's over 10% operational growth. And get this, Jordan, nine different products posted double-digit growth this quarter.
**JORDAN:** Nine! That's the kind of breadth investors love to see. It's not just one blockbuster carrying the whole company. And because of that strength, they raised full-year revenue guidance again — now up $800 million since the start of the year total, landing around $67.8 billion for 2026.
**ALEX:** They also bumped up EPS guidance to a range of $13.95 to $13.99 for the full year. And here's the cherry on top — a 5.2% dividend increase, bringing the quarterly payout to $1.82 per share starting in February 2027.
**JORDAN:** Since AbbVie's inception as a standalone company, that dividend has grown over 350%. That's a pretty remarkable track record for income-focused investors.
**ALEX:** Let's talk about where the growth is actually coming from, because the Humira patent cliff story is basically old news at this point.
**JORDAN:** Completely. Humira sales were down 30.6% this quarter to $683 million — but that barely matters anymore because immunology overall grew 16.6% to $9.2 billion. Skyrizi alone did nearly $5.8 billion, up almost 23%. Rinvoq did $2.7 billion, up over 24%.
**ALEX:** And management keeps raising Skyrizi guidance — this is the third time this year they've bumped it up. CEO Rob Michael made a great point on the call: Skyrizi and Rinvoq combined are adding $6 billion in growth this year despite being eight years on the market and facing new oral competition.
**JORDAN:** That's the story investors should really sit with. Everyone worried about biosimilars and new entrants cannibalizing AbbVie's immunology franchise, and instead these two drugs are capturing roughly half of all new or switching patients in psoriasis and IBD. They just approved a new subcutaneous induction dosing for Skyrizi in Crohn's disease, and the data was described as "striking" — better endoscopic remission rates than their own IV formulation.
**ALEX:** Neuroscience is the other big story — up almost 20% to $3.4 billion. Vraylar, Ubrelvy, Qulipta all posting strong double-digit growth. And they just launched a new Parkinson's drug called Juvmo.
**JORDAN:** Juvmo is interesting because it targets different dopamine receptors than older Parkinson's drugs — D1/D5 instead of D2/D3 — which means lower rates of nasty side effects like impulse control disorders and sleep attacks. Combined with their existing Parkinson's drug Vyalev, management thinks this franchise alone could hit $5 billion in peak sales.
**ALEX:** Now let's touch on the big strategic move this quarter — the completed acquisition of Apogee Therapeutics.
**JORDAN:** Yeah, this is AbbVie doubling down on immunology depth. Apogee brings dermatology and respiratory assets, with the lead drug — zumilokibart — heading into Phase III trials for atopic dermatitis later this year. Rob Michael was pretty clear on the call that going forward, they're looking at bolt-on deals rather than another mega-merger like Allergan. Think "add depth, not breadth."
**
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet